Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.
The company was established in 2007 and currently employs around 900 professionals, of which over 40% hold a PhD degree. The research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia. Our international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.
Selvita provides integrated drug discovery support ranging from hit identification, hit to lead, lead optimization phase up to nomination of a preclinical candidate. We specialize in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs. From the therapeutic area perspective, Selvita has a bread expertise and track record in oncology, infectious diseases, inflammation, fibrosis, respiratory diseases, and neuroscience.
In addition, Selvita offers state-of-the-art analytical services supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and CMC processes by providing contract laboratory services for testing. We have a diverse analytical instrumentation and expertise portfolio, allowing us to meet varied demands, including testing of starting materials, drug substances, intermediates, and final products of small and large molecules. Selvita complies with GMP and GLP requirements to meet the highest industry standards.
Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For more information, please visit our HomePage: www.selvita.com.